De Novo device
Lenire Tinnitus Treatment Device
Neuromod Devices Limited · Combined Acoustic And Electrical External Stimulation Device For The Relief Of Tinnitus (QVN, Class II) · First FDA decision Mar 6, 2023, newest Mar 6, 2023Tinnitus
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
3
Naming "Lenire"
MAUDE reports
0
Brand "Lenire", since 2015
PubMed studies
4
Mentioning "Lenire"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Lenire Tinnitus Treatment Device
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Cavernous Nerves Electrical Stimulation with Penile PlethysmographyNational analysisReview closedCAG-00311NUpdated Sep 17, 2026
- Pelvic Floor Electrical Stimulation for Urinary IncontinenceNational analysisReview closedCAG-00021NUpdated Sep 15, 2026
- Neuromuscular Electrical Stimulation (NMES) for Spinal Cord InjuryNational analysisReview closedCAG-00153RUpdated Sep 15, 2026
- Electrical Stimulation for Fracture HealingNational analysisReview closedCAG-00043NUpdated Sep 14, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP)National determinationOn the books160.27Updated Feb 10, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative PainNational determinationOn the books10.2Updated Dec 2, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Lenire", any status and sponsor, newest update first.
- Investigating EEG as a Biomarker for Tinnitus Improvement After Bimodal StimulationActive, not recruiting
University of MinnesotaAcademic, hospital or other
NCT07158034 · 10 participants · Start Oct 3, 2025 · Primary completion Nov 30, 2026
Device: Lenire Device · For: Tinnitus
Sites: Minneapolis, Minnesota
- Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With TinnitusCompleted
University of MinnesotaAcademic, hospital or other
NCT05518682 · 26 participants · Start Sep 19, 2022 · Primary completion Aug 25, 2023
Device: Lenire bimodal stimulation device · For: Tinnitus
Sites: Minneapolis, Minnesota
Neuromod Devices Ltd.Not on our public-company list
NCT05227365 · 112 participants · Start Mar 21, 2022 · Primary completion Sep 6, 2022
Device: Lenire · For: Tinnitus
Sites: Ghent, Belgium; Hanover, Germany; Dublin, Ireland
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Lenire", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QVN
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Lenire"[tiab]. The summary above synthesizes these.
- Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial.
Boedts M, Buechner A, Khoo SG, et al. · Nat Commun · 2024Multicenter Study, Research Support, Non-U.S. Gov't
- Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting.
McMahan EE, Lim HH · Commun Med (Lond) · 2025
- Bimodal Neuromodulation for Tinnitus in a Clinical Practice Setting: Clinically Significant Benefit for Patients With Moderate or Worse Symptoms.
Kasper CA, May JM, Crossland NE, et al. · Am J Audiol · 2026
- Early Post-Market Surveillance of Bimodal Neuromodulation for Tinnitus.
Srivatsa A, Gathman TJ, Stefan A, et al. · Otolaryngol Head Neck Surg · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.